View
358
Download
0
Category
Preview:
Citation preview
A New Ocular Therapeutics ToolLooking for business opportunities
Timo KangastupaCEO, Visionisti Oynon-confidential
““Dose reduction and convenience
technologies are needed”
Kevin BuehlerFormer Alcon Division Head
Novartis Investor Day22 November 2013
A new solution for suprachoroidal injections
Suitable also for precisely transmitting heat, cold, electricity, light or other energy to directly stimulate, damage, or heal a specific tissue or for diagnostic purposes
30-50M patients with AMDout of whom 3-10M have the wet form - an overwhelming burden
67M with glaucomauveitis, corneal infections, gene therapy, stem cell treatments, and others
350M with diabetic retinopathypotential therapies for oedemas, RVO, and others
10% continued growthprojected, driven by new indications
““An effective drug delivery system for the
back of the eye should embody four general characteristics. Current methods cannot meet all of these requirements.”
- SR Patel, Co-founder Clearside Biomedical
1.Minimally invasive and safe
to avoid the complications caused by the procedure
Fulfilled by Visionist’s Tool:
• No need for a surgical operation – in office procedure
• Closes the entry wound automatically
• Minimizes the risk for endophthalmitis
• Less discomfort for the patients and faster wound healing
2.Well targeted to the
desired tissueshigh bioavailability while reducing
adverse events and toxicity
Fulfilled by Visionist’s Tool:
• Direct contact to the sites of therapeutic action
• Effective distribution and faster influence
• Limits exposure to other regions of the eye
• Less side effects and complications
• Does not effect the optical axis
3.Capable of sustained delivery
to reduce the frequency of administration and allow for better therapeutic control
Fulfilled by Visionist’s Tool:
• Higher drug concentrations for months
• More accurate dosing and dose sparing
• Suitable for sustained delivery and implants
• Eases the treatment burden for all parties
4.Simple
to reduce errors and compliance problems
Fulfilled by Visionist’s Tool:
• Disposable product with great margins
• Stabilizes the eye and keeps the lids open
• Standardizes the procedure and increases the efficiency
• Repeatable, Faster, Easier and Safer
• Enables administration by trained non-physicians?
Proof of concept – ex vivo porcine eyes
• The distribution of methylene blue in the suprachoroidal space (black arrows).
• 1 μm FluoSpheres (below in red) were localized in the suprachoroidal space.
CONCLUSIONS: The proprietary ocular injection device is well suitable for precise delivery of injected material into suprachoroidal space.
Data on file
IPR
FreshPCT patent
pendingfor the Device and Methods
No countries chosen yet
FTO
Thoroughlyanalysed
No obstacles
Registered Community
Designs in EU
Business opportunities
Rare technology, rare opportunity.
Superior to the known alternatives for suprachoroidal drug delivery.
Visionisti Oy is open for any kind of business opportunities you are interested in.
Visionisti presents a novel delivery platform for your molecules, with no limitations.
Thank you!Please get in touch with any questions
You can reach me at timo@vsn.st
Recommended